Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter TAG-72 (Minretumomab Biosimilar) Antikörper

Reaktivität: Human FACS, IHC, RIA, WB Wirt: Maus Monoclonal unconjugated Recombinant Antibody
Produktnummer ABIN7072523
  • Target Alle TAG-72 (Minretumomab Biosimilar) Produkte
    TAG-72 (Minretumomab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    Human
    Wirt
    • 1
    Maus
    Klonalität
    • 1
    Monoklonal
    Konjugat
    • 1
    Dieser TAG-72 (Minretumomab Biosimilar) Antikörper ist unkonjugiert
    Applikation
    Flow Cytometry (FACS), Immunohistochemistry (IHC), Radioimmunoassay (RIA), Western Blotting (WB)
    Verwendungszweck
    Anti-TAG-72 [Minretumomab (CC49 )], Mouse IgG1, kappa
    Spezifität
    This antibody is specific for the disaccharide sialyl Tn epitope of human TAG-72. TAG-72 is expressed on a wide range of human carcinomas, including colorectal cancers.
    Produktmerkmale

    Original Species of Ab: Mouse

    Original Format of Ab: IgG1

    Aufreinigung
    Protein A affinity purified
    Immunogen
    This antibody was raised by immunising BALB/c mice with TAG-72 purified from LS-174T human carcinoma xenograft.
    Isotyp
    IgG1 kappa
  • Applikationshinweise
    The reactivity of this antibody with colon cancer extract and purified TAG-72 has been confirmed in solid-phase radioimmunoassays, and its reactivity with formalin-fixed carcinoma tissue sections confirmed in immunoperoxidase studies (Muraro et al, 1988). In flow cytometric analysis of freshly-isolated human carcinoma cells, this antibody reacts more strongly than the anti-TAG-72 MAb B72.3 (Muraro et al, 1988). Equally, flow cytometric analyses using this antibody have revealed that TAG-72 is expressed by certain haematopoietic cell lines (Nicolet et al, 1997). In western blot analysis, this antibody reacts with TAG-72 (Muraro et al, 1988). A humanised version of this antibody has been shown to be safe and sensitive in detecting recurrent colorectal carcinomas in radioimmunoguided surgery (Agnese et al, 2004), while radioimmunotherapy with an iodine-131-conjugated antibody has been shown to have a significant therapeutic effect on metastatic colon carcinoma in Phase I trials (Divgi et al, 1995).
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Konzentration
    1 mg/mL
    Buffer
    PBS with 0.02 % Proclin 300.
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target
    TAG-72 (Minretumomab Biosimilar)
    Abstract
    TAG-72 (Minretumomab Biosimilar) Produkte
    Hintergrund
    CA 72-4, Tumor-associated antigen 72, TAG72, Tumor-associated glycoprotein 72
Sie sind hier:
Kundenservice